What happens when HER2-Positive Breast Cancer treatment stops working

When HER2-Positive Breast Cancer Treatment Stops Working

This is an important question that many patients face. Let me explain what happens and what options typically exist based on current medical evidence.

How Treatment Resistance Develops

When HER2-positive breast cancer initially responds to anti-HER2 therapy (like trastuzumab/Herceptin), the cancer cells are being effectively targeted. However, cancer cells are remarkably adaptable. According to clinical evidence, when you give a trastuzumab-based drug, the cancer will find a way to evade that treatment, and it will tend to upregulate HER3 levels — meaning the cancer cells activate a different growth pathway to survive.

This is called acquired resistance, and it's a known challenge in HER2-positive breast cancer treatment.

What Doctors Typically Do

When resistance develops, oncologists generally follow this clinical reasoning:

STEP 1: Identify the Resistance Mechanism

• Your doctor may recommend repeat testing (biopsy or liquid biopsy) to understand what's changed
• They'll look for new mutations or changes in protein expression that explain why the previous drug stopped working
• This helps determine the best next approach

STEP 2: Consider Combination or Sequential Therapy According to clinical case reports, when single-agent trastuzumab stops working, doctors often:

• Add a second anti-HER2 drug (like pertuzumab) to create a dual-targeting approach
• Switch to newer anti-HER2 agents like trastuzumab deruxtecan (Enhertu), an antibody-drug conjugate that delivers chemotherapy directly to HER2-positive cells
• Combine anti-HER2 therapy with other targeted drugs to block multiple growth pathways simultaneously

One documented case showed that when a patient developed resistance to trastuzumab alone, adding pertuzumab created a dual blockade. However, the cancer adapted again by upregulating additional resistance mechanisms, so additional drugs were added — ultimately resulting in significantly extended survival (39 months vs. the typical <12 months for advanced gastric cancer).

STEP 3: Explore Your HER2 Protein Levels This is increasingly important: not all HER2-positive cancers have the same level of HER2 expression. Some newer drugs work better for different HER2 expression levels:

• High HER2 expression: Anti-HER2 monoclonal antibodies and antibody-drug conjugates
• HER2-low expression: Trastuzumab deruxtecan (Enhertu) has shown benefit even in HER2-low tumors, with overall survival of 24 months compared to 17 months with chemotherapy alone

Questions to Ask Your Oncologist

When your treatment stops working, these questions can help guide your care:

1. "Can we do repeat testing to understand what's changed in my cancer?" (This might be a biopsy or liquid biopsy)

2. "What is my current HER2 expression level, and does that change which drugs might work best?"

3. "What are the options for combination therapy — can we add another anti-HER2 drug or switch to a different one?"

4. "Are there clinical trials available for HER2-positive breast cancer with resistance to my current treatment?"

5. "What is the expected timeline and goals of the next treatment approach?"

Important Context

Your specific situation requires your oncologist's evaluation of:

• How long your cancer responded to the first treatment
• Your overall health and ability to tolerate additional therapy
• The specific characteristics of your tumor (stage, location, other mutations)
• Your preferences and goals for treatment

Your oncologist will determine the most appropriate approach for YOUR case based on the complete clinical picture, not just the general patterns described here.

---

Sources:

• Clinical Guidance from Proteomics (Sheeno Thyparambil, CancerPatientLab Webinar #26) — documents cases of HER2-positive gastric cancer with acquired resistance and multi-drug combination approaches
• Proteomic Testing for Cancer: How Protein Analysis Guides Treatment (Sheeno Thyparambil) — discusses HER2 expression levels and treatment selection
• Novel Therapies and New Directions in Pancreas Cancer, 2024 (Eileen O'Reilly, MD) — discusses trastuzumab deruxtecan (Enhertu) approval and clinical applications

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.